Skip to main content
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TVRD ISIN · US1407553072 LEI · 549300COVOY41P0GZ881 IL Manufacturing
Open in API
Filings indexed 781 across all filing types
Latest filing 2024-12-18 Major Shareholding Noti…
Country US United States of America
Listing IL TVRD

About Tvardi Therapeutics, Inc.

https://tvarditherapeutics.com

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered, small molecule therapies. The company's core approach is targeting STAT3 (Signal Transducer and Activator of Transcription 3), a key regulatory protein implicated in the progression of various diseases. Tvardi's therapeutic pipeline is designed to address conditions with significant unmet medical needs, including various forms of cancer and fibrosis-driven diseases. Its clinical trials are evaluating potential treatments for indications such as liver cancer and idiopathic pulmonary fibrosis (IPF).

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification
2024-12-18 English
S-4
Merger & Acquisition Classification · 100% confidence The document is a Form S-4 registration statement filed with the SEC, which is used for securities registration in connection with mergers and acquisitions. It includes detailed information about the merger between Cara Therapeutics, Inc. and Tvardi Therapeutics, Inc., including proposals for stock issuance, reverse stock split, and amendments to the certificate of incorporation. The document also contains proxy statement/prospectus information related to the merger transaction. This type of filing is specifically related to merger and acquisition activity and is not a general annual report, earnings release, or proxy solicitation alone. Therefore, the appropriate classification is 'Merger & Acquisition' (MA). The document length and content confirm it is the actual filing, not just an announcement or summary.
2024-12-18 English
FORM 8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Cara Therapeutics, Inc. dated December 17, 2024. The content details the entry into a material definitive agreement, specifically a merger agreement with Tvardi Therapeutics, Inc. It describes the terms of the merger, stockholder matters, support agreements, lock-up agreements, and conditions for closing. The document is a regulatory filing announcing a significant corporate transaction (merger) but is not itself a merger proxy statement or a full merger filing like a DEFM14A or Form S-4. It is a current report disclosing material events as required by the SEC. According to the filing definitions, announcements and documents related to merger proposals or takeover bids fall under M&A Activity (Code: TAR). Since this is a detailed announcement of a merger agreement and related arrangements, the appropriate classification is M&A Activity (TAR). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a proxy solicitation but a substantive merger announcement.
2024-12-18 English
425 Filing
M&A Activity Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Cara Therapeutics, Inc. dated December 17, 2024. The content details the entry into a material definitive agreement, specifically a merger agreement with Tvardi Therapeutics, Inc. It describes the terms of the merger, stockholder arrangements, support agreements, lock-up agreements, and conditions for closing. The document is a regulatory filing reporting a significant corporate transaction (merger) but is not itself a merger proxy statement, tender offer, or detailed merger communication form. It is a current report announcing the merger agreement and related arrangements. According to the filing definitions, announcements and documents related to merger proposals or takeover bids fall under the category 'M&A Activity' (Code: TAR). The document is not a full merger proxy statement (MA), nor is it a simple announcement of a report (RPA), but a detailed announcement of a merger agreement. Therefore, the appropriate classification is 'TAR'. The document length (15,000 characters) and detailed content support a high confidence in this classification.
2024-12-18 English
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC by Cara Therapeutics, Inc. dated November 19, 2024. The content focuses on a notice from Nasdaq regarding the company's non-compliance with listing requirements, specifically the minimum stockholders' equity and minimum bid price requirements. It discusses the potential delisting process, compliance plans, and timelines. There are no financial statements or detailed financial data included, only regulatory and compliance information related to listing status. This matches the definition of a Delisting Announcement (DLST), which is an official notice that the company's stock will be removed from an exchange or is at risk of removal. The document is not an annual or quarterly report, audit report, or earnings release, nor is it a simple announcement of a report publication. Therefore, the correct classification is DLST with high confidence.
2024-11-22 English
10-Q
Interim / Quarterly Report Q3 2024
2024-11-14 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.